Delivering Trustworthy, Actionable Digital Continuing Medical Education, Together.
PlatformQ Health Education is excited to present Dyslipidemia, Diabetes, And Cardiovascular Risk: Clinical Strategies and Evolving Treatments, a free online CME session produced in partnership with the American Society for Preventive Cariology and accredited by the Joslin Diabetes Center (JOS). The program will air live on two of PlatformQ Health’s Education learning channels – CardioCareLive and DiabetesSeriesLive – on Wednesday June 3rd at 2pm ET and be available for on-demand viewing through December 2020.
Expert faculty Dr. Richard S. Beaser, Senior Staff Physician and Medical Director of CME at Joslin Diabetes Center, Dr. Om P. Ganda, Medical Director of the Lipid Clinic & Chair of the Clinical Oversight Committee at Joslin Diabetes Center, and Dr. Deepak L. Bhatt Executive Director of Interventional Cardiovascular Programs at Brigham & Women’s Hospital Heart & Vascular Center and Professor of Medicine at Harvard Medical School will explain the data behind the latest cardiovascular risk reduction recommendations for people with type 2 diabetes.
About the Session
People with diabetes have a high risk for the development of adverse cardiovascular (CV) outcomes. Non-specialists, and even some specialists in the treatment of these patients, have seen multiple pivotal trials, treatment guidelines, and therapeutic paradigms for people with diabetes evolve in the last few years. Lately, much emphasis has been given to the cardiovascular implications of antidiabetes medications.
The advancement of treatments for CV risk reduction mandates that all providers who treat people with heightened risk from metabolic conditions such as diabetes, fully understand and implement these new guidelines and the latest evidence-based recommendations for the use of newer treatment tools.
“We are excited to present this CME session with Joslin Diabetes Center and the American Society of Preventive Cardiology and be able to help the leaders in the space keep clinicians up to date on the advancement of treatments for patients a CV risk,” said Robert Rosenbloom, President and CEO of PlatformQ Health Education.
Upon completion of the program, HCP participants will be able to:
- Describe key treatment recommendations in accordance with current guidelines and recommendations from major expert groups, and explaining how they would apply to type 2 diabetes treatment design that optimizes cardiovascular risk reduction
- Initiate and advance treatments for diabetes and dyslipidemia using newer pharmacotherapies with evidence-based benefits in blunting cardiovascular risk, including GLP-1 receptor agonists, SGLT2 inhibitors, icosapent ethyl, and PCSK9 inhibitors
- Overcome clinical barriers to the timely and effective therapeutic initiation of the latest antidiabetes and dyslipidemia lipid treatments that have demonstrated cardiovascular benefits